KR20250097960A - 질환의 치료를 위한 포스포이노시티드 3-키나제 (pi3k)의 알로스테릭 크로메논 억제제 - Google Patents

질환의 치료를 위한 포스포이노시티드 3-키나제 (pi3k)의 알로스테릭 크로메논 억제제 Download PDF

Info

Publication number
KR20250097960A
KR20250097960A KR1020257018231A KR20257018231A KR20250097960A KR 20250097960 A KR20250097960 A KR 20250097960A KR 1020257018231 A KR1020257018231 A KR 1020257018231A KR 20257018231 A KR20257018231 A KR 20257018231A KR 20250097960 A KR20250097960 A KR 20250097960A
Authority
KR
South Korea
Prior art keywords
cancer
salt
peak
compound
theta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257018231A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 앤드류 코츠
로리 라켈 힐덴
지즐라이니 쿠미네크
Original Assignee
페트라 파마 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 페트라 파마 코포레이션 filed Critical 페트라 파마 코포레이션
Publication of KR20250097960A publication Critical patent/KR20250097960A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/03—Monoamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020257018231A 2022-11-02 2023-10-31 질환의 치료를 위한 포스포이노시티드 3-키나제 (pi3k)의 알로스테릭 크로메논 억제제 Pending KR20250097960A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263421636P 2022-11-02 2022-11-02
US63/421,636 2022-11-02
US202263423879P 2022-11-09 2022-11-09
US63/423,879 2022-11-09
PCT/US2023/036445 WO2024097205A1 (en) 2022-11-02 2023-10-31 Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease

Publications (1)

Publication Number Publication Date
KR20250097960A true KR20250097960A (ko) 2025-06-30

Family

ID=88978500

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020257018231A Pending KR20250097960A (ko) 2022-11-02 2023-10-31 질환의 치료를 위한 포스포이노시티드 3-키나제 (pi3k)의 알로스테릭 크로메논 억제제

Country Status (8)

Country Link
EP (1) EP4612136A1 (enExample)
JP (1) JP7712994B2 (enExample)
KR (1) KR20250097960A (enExample)
CN (1) CN120476112A (enExample)
AU (1) AU2023373670A1 (enExample)
MX (1) MX2025005020A (enExample)
TW (1) TWI887826B (enExample)
WO (1) WO2024097205A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119874676A (zh) * 2023-10-25 2025-04-25 海创药业股份有限公司 一种pi3k抑制剂及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA21528A1 (fr) * 1988-04-06 1989-12-31 Lipha Composants substituants du flavonoide, leurs sels, leurs manufactures et produits contenant ces matieres .
NZ538420A (en) * 2002-08-16 2007-06-29 Kinacia Pty Ltd Inhibition of phosphoinositide 3-kinase beta
US8519155B2 (en) * 2008-10-31 2013-08-27 C-A-I-R Biosciences Gmbh Choline and tromethamine salt of licofelone
EP3369730B1 (en) * 2012-11-05 2020-08-05 Emory University 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto
KR102485620B1 (ko) * 2017-03-03 2023-01-09 길리애드 사이언시즈, 인코포레이티드 Acc 억제제 및 그의 고체 형태를 제조하는 방법
AR121719A1 (es) * 2020-04-03 2022-06-29 Petra Pharma Corp Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
AU2022268900B2 (en) * 2021-05-03 2024-12-19 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease

Also Published As

Publication number Publication date
MX2025005020A (es) 2025-08-01
TWI887826B (zh) 2025-06-21
EP4612136A1 (en) 2025-09-10
AU2023373670A1 (en) 2025-05-15
TW202432100A (zh) 2024-08-16
JP7712994B2 (ja) 2025-07-24
JP2024067008A (ja) 2024-05-16
WO2024097205A1 (en) 2024-05-10
CN120476112A (zh) 2025-08-12

Similar Documents

Publication Publication Date Title
JP7383652B2 (ja) Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用
JP6457623B2 (ja) ２，４−二置換７Ｈ−ピロロ［２，３−ｄ］ピリミジン誘導体、その製造方法および医薬における使用
CN115677702B (zh) 三并环化合物及其药物组合物和应用
CN110698461B (zh) 第三代egfr抑制剂的制备方法
EA038195B1 (ru) Малатная соль n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида и ее применение для лечения рака почек и печени
US10202364B2 (en) Forms and compositions of an ERK inhibitor
EP3327014A1 (en) Egfr inhibitor and pharmaceutically acceptable salt and polymorph thereof, and use thereof
TW202313034A (zh) Egfr抑制劑的鹽、晶型及其組合物和應用
WO2025162135A1 (zh) Kras g12c突变蛋白嘧啶并噻喃二酮类抑制剂的制备及其应用
CN116390728B (zh) 喹唑啉衍生物及其制备方法和用途
CN117143093A (zh) 一种蛋白降解剂及其制备方法和用途
CN118791505A (zh) 一种含肟结构的杂环化合物及其制备方法与用途
JP7712994B2 (ja) 疾患の治療用のホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリッククロメノン阻害剤
CN118076614A (zh) 一种egfr抑制剂的多晶型
KR20250105413A (ko) 질환의 치료를 위한 포스포이노시티드 3-키나제 (pi3k)의 알로스테릭 크로메논 억제제
WO2024149275A1 (zh) Kras抑制剂化合物
KR20250012078A (ko) 상피 성장 인자 수용체 억제제의 염 및 결정 형태
JP7034430B2 (ja) 重水素化インドールアミン２，３－ジオキシゲナーゼ阻害剤及びその使用
WO2021078141A1 (zh) 新型嘌呤衍生物及其中间体与制备抗癌症药物的应用
WO2025231053A1 (en) Solid forms of 6-chloro-3-[(1r)-1-[3,6-dimethyl-2-(2-methylindazol-5-yl)-4-oxo-chromen-8-yl]ethoxy]pyridine-2-carboxamide
CN116535423B (zh) 抑制/诱导降解egfr激酶的化合物及其药物组合物和应用
WO2018141296A1 (en) Protein tyrosine kinase modulators salt, crystallographic forms, and uses thereof
WO2019149128A1 (zh) 作为抗肿瘤药物的5-氯-2,4-嘧啶衍生物
WO2023203374A1 (en) [1,2]selenazolo[2,3-a]pyridin-8-ium inhibitors of pyruvate kinase isoform m2
JP2025526715A (ja) ピリジノピリミジノン化合物の結晶、その酸塩、その酸塩の結晶及び使用

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20250602

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250602

Comment text: Request for Examination of Application

PG1501 Laying open of application